Skip to content

Monitor Immune Microenvironment and systemic immune effects in pediatric Brain tumors

Monitor Immune Microenvironment and systemic immune effects in pediatric Brain tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON24486
Enrollment
60
Registered
2020-10-14
Start date
2021-04-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric brain tumors

Interventions

None listed

Sponsors

Princess Máxima Center for Pediatric Oncology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Age 0 – 18 years at inclusion - Newly diagnosed brain tumor or relapse of a brain tumor - MRI representing an image of a high grade brain tumor (high grade glioma, ependymoma, ATRT, medulloblastoma, or otherwise high grade) OR CNS tumor where based on MRI images the judgement of high grade versus low grade can’t be made. NB in case MRI imaging prior to biopsy and/or resection is not feasible, the patient can be included based on CT imaging and clinical assessment - Clinical indication for tumor biopsy/resection - Written (parental) informed consent

Exclusion criteria

Exclusion criteria: - Suspected germ cell tumor on radiology or based on tumor markers (aFP, ßHCG) - Suspected craniopharyngioma on radiology - Clear characteristics of low grade tumor

Design outcomes

Primary

MeasureTime frame
Descriptive characterisation of lymphoid and myeloid subsets and activation status in different compartment, e.g. tumor microenvironment, blood, bone marrow, and CSF at different timepoints

Secondary

MeasureTime frame
Descriptive characterisation of lymphoid and myeloid subsets and activation status in different compartment, e.g. tumor microenvironment, blood, bone marrow, and CSF before after and during treatment Multivariate regression analysis of lymphoid and myeloid subsets and activation status in the different compartments in relation to overall survival and event free survival (event = relapse or death of any cause) response to therapy

Contacts

Public ContactRaoull Hoogendijk

Princess Máxima Center for Pediatric Oncology

r.hoogendijk@prinsesmaximacentrum.nl+31647959515

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)